DJIA 17,164.95 -251.90 -1.45%
NASDAQ 4,635.24 -48.17 -1.03%
S&P 500 1,994.99 -26.26 -1.30%
market minute promo

Express Scripts (NASDAQ: ESRX)

company name or ticker
Company Photos
(Click to zoom)

Evercore ISI Analyst: 160,000 Patients Affected by AbbVie Hepatitis Pact

Why Achillion Pharmaceuticals Shares Collapsed by 25% Today

Achillion Pharmaceuticals reported mixed results from clinical trials that sent shares tumbling.

Gilead Sciences Plunges for Second Day In A Row: What Wall Street's Saying

Record High for Dow as Third-Quarter GDP Signals Domestic Health

Analysts Predict Big Value Trap for Gilead Investors

Express Scripts Hates Gilead Sciences, Loves AbbVie

Express Scripts ditches Gilead Sciences' hepatitis C treatments from its drug formulary in favor of AbbVie.

Deutsche Bank Analyst Sees Gilead Sciences Vs. AbbVie 'Price War'

AbbVie Inc. Throws First Punch in Hep C Price War With Gilead Sciences, Inc.

Express Scripts makes AbbVie's Viekira Pak its exclusive hepatitis C drug, excluding Gilead's Harvoni.

AbbVie Competes On Price

Investors Cheer Dow 18,000, but Big Pharma Gets Left Behind

The Dow topped a new milestone, but big pharmaceutical stocks had nothing to celebrate today.